Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

Background In the international, phase III, randomized, double-blind CORRECT trial, regorafenib significantly prolonged overall survival (OS) versus placebo in patients with metastatic colorectal cancer (mCRC) that had progressed on all standard therapies. This post hoc analysis evaluated the effica...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Yoshino, Takayuki, Komatsu, Yoshito, Yamada, Yasuhide, Yamazaki, Kentaro, Tsuji, Akihito, Ura, Takashi, Grothey, Axel, Van Cutsem, Eric, Wagner, Andrea, Cihon, Frank, Hamada, Yoko, Ohtsu, Atsushi
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2014
Assuntos:
Phase III Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4434855/
https://ncbi.nlm.nih.gov/pubmed/25213161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0154-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados